- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03645915
GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors (GLUT1)
GLUT1: A Novel Tool Reflecting Proliferative Activity of Lung Neuroendocrine Tumors
Lung neuroendocrine tumor (LNT) represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker.
GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.
The team have assessed the GLUT1 immunohistochemical staining in 36 LNT and to assess its diagnostic value.
Study Overview
Detailed Description
The (LNT) Lung neuroendocrine tumor represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker.
GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with neuroendocrine tumors
Exclusion Criteria:
- Patients without neuroendocrine tumors
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the GLUT1
Time Frame: 5years
|
The objective of this study is to assess the GLUT1 staining in cohort of 36 cases of neuroendocrine tumors by immunohistochemistry and to assess its diagnostic interest.
|
5years
|
Collaborators and Investigators
Investigators
- Principal Investigator: henri sevestre, MD, PhD, CHU Amiens
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI2017_843_0043
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Tumor
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
DeuterOncologyRecruitingAdult Solid Tumor | Lung Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Non-small Cell Carcinoma | Refractory Tumor | Hereditary Renal Papillary CancerFrance, Belgium, Netherlands
-
Navire Pharma Inc., a BridgeBio companyAmgenRecruitingNon Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Metastatic NSCLCSpain, Australia, France, Denmark, Greece, Italy, Netherlands
-
Guangzhou Institute of Respiratory DiseaseRecruitingPoor Performance Status | Malignant Tumor of LungChina
-
University of Roma La SapienzaRecruitingLung Cancer | Circulating Tumor Cell | Spreading of TumorItaly
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Roswell Park Cancer InstituteNeuroEndocrine Tumor Research Foundation (NETRF)RecruitingLung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid TumorUnited States
-
Peking University Cancer Hospital & InstituteActive, not recruiting
-
Centre Hospitalier Universitaire de BesanconCompletedRenal Tumor | Bone Tumor | Lung TumorFrance
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
Clinical Trials on Immunohistochemistry
-
Assiut UniversityNot yet recruiting
-
Groupe Francais De Pneumo-CancerologieCompletedLarge Cell Lung Cancer | Neuroendocrine Carcinoma of Lung (Diagnosis)France
-
University Hospital, GrenobleInstitut National de la Santé Et de la Recherche Médicale, FranceNot yet recruitingFetal Growth Retardation | Pre-eclampsia | Pre-Term
-
Centre Hospitalier Departemental VendeeCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Completed
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingHead and Neck CancerFrance
-
St. Justine's HospitalRecruitingHirschsprung Disease | Ganglion | Hirschsprung Disease, Long-Segment | HypoganglionosisCanada
-
Hillel Yaffe Medical CenterUnknown
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruiting